Novartis has broadened its collaboration with Monte Rosa Therapeutics by licensing an exclusive molecular glue degrader targeting an undisclosed protein for immune-mediated diseases. The deal includes options for two additional preclinical immunology programs with potential total milestones of $5.7 billion. This follows their 2024 agreement focused on VAV1-targeting degraders. Monte Rosa’s platform, QuEEN, enables development of novel protein degradation therapies, highlighting continued interest in targeted protein degradation strategies within immunology.